BioSig to Present at the 26th Annual International AF Symposium
January 15 2021 - 9:32AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company will be presenting at the
26th Annual International Atrial Fibrillation Symposium, held
virtually on January 29-31, 2021.
Clinical observations collected with BioSig’s PURE
EPTM System will be presented by G. Joseph Gallinghouse, M.D.,
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center,
during Spotlight Session: Early Stage and Emerging New Technologies
and Drugs in Cardiac EP on January 29, 2021, from 2:40-3:40pm
ET.
More than 470 patient cases have been conducted with the PURE
EPTM System to date across seven clinical sites in the US. Dr.
Gallinghouse is one of the most experienced PURE EPTM physician
users, having worked with the technology since 2019.
This year, the AF Symposium will be streamed live and can be
attended free of charge. To register for the event, please follow
this link:
https://events.r20.constantcontact.com/register/eventReg?oeidk=a07ehfsps50a7702ca6&oseq=&c=&ch=
“The annual AF Symposium is one of the industry's highlights,
and we are particularly grateful to the organizers for opening up
this outstanding event to the broader audience in 2021. All
stakeholders, including patients and the financial community, are
being presented with a unique opportunity to attend a highly
educational industry event that would normally be reserved for
peer-to-peer engagement. We look forward to contributing to the
excellent scientific program and learning about the latest clinical
advances from the faculty and our peers,” commented Kenneth L.
Londoner, Chairman, and CEO of BioSig Technologies, Inc.
About The 26th Annual International AF
Symposium This intensive, highly focused three-day
symposium brings together the world’s leading medical scientists to
share in a highly interactive environment the most recent advances
in the field of atrial fibrillation. The primary objective of the
meeting is to provide attendees with a thorough and practical
course on the current state of the art in the field of atrial
fibrillation in a scholarly and collegial atmosphere, as well as an
opportunity to network with colleagues and faculty between
sessions. More information about the event on
www.afsymposium.com. About BioSig Technologies
BioSig Technologies is a medical technology company commercializing
a proprietary biomedical signal processing platform designed
to improve signal fidelity and uncover the full range of ECG
and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EPä System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024